Format

Send to

Choose Destination
Arq Bras Endocrinol Metabol. 2006 Apr;50(2):327-33. Epub 2006 May 23.

Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.

Author information

1
Nephrology Division, Hospital do Rim e Hipertensão, Fundação Oswaldo Ramos, UNIFESP, São Paulo, SP, Brazil. artur.ribeiro@hrim.com.br

Abstract

Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago. During this period they were evaluated not only in terms of efficacy and safety but also in several large studies with clinical outcomes. They are efficacious in all clinical forms of hypertension and are effective also in all ethnic groups. Cardiovascular and renal protection in proteinuric diabetic nephropathy beyond blood pressure reduction was proved in major clinical studies: Losartan Intervention For Endpoint reduction in hypertension study (LIFE), Reduction of Endpoint in Non-Insulin dependent Diabetes Mellitus with the AII Antagonist Losartan (RENAAL) and Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT). Their blood pressure independent protective effect is also mentioned by the blockade of AT1 receptor. As a class AIIs have a tolerability profile similar to placebo.

PMID:
16767299
DOI:
/S0004-27302006000200019
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center